Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC

Podcast

In Partnership With:

Dr Dy discusses the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer, ongoing research with tusamitamab ravtansine, and the potential role of competing docetaxel-based combination strategies in the second-line setting.

Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Sanofi, we had the pleasure of speaking with Grace Dy, MD, to discuss the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer (NSCLC).

Dr Dy is the chief of thoracic oncology and a professor of medicine in the Department of Medicine at Roswell Park Comprehensive Cancer Center in Buffalo, New York.

In our exclusive interview, Dr Dy discussed ongoing research with tusamitamab ravtansine and its known safety profile in NSCLC, the importance of incorporating specialized tissue collection into daily workflows, and the potential role of competing docetaxel-based combination strategies in the second-line setting.

___

That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Sanofi. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
George R. Simon, MD, FACP, FCCP
Ashish Saxena, MD, PhD
Eric Vallieres, MD, FRCSC
Benjamin Levy, MD
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.